THE CLINICAL AND HUMANISTIC IMPACT OF PEMBROLIZUMAB IN THE CZECH REPUBLIC: A POPULATION-LEVEL PAN-TUMOR MODELING STUDY
Author(s)
Tomas Mlcoch, MSc.1, Leona Popelkova, PharmD1, Autumn Hoang, MSc.2, Amy Barber, MSc.2, Catarina Neves, MSc.3, Joao Pedro Ferreira, MSc.4, Bernardo Rodrigues, MSc.4, Annabelle Davies, MSc5, Vivek Khurana, MD MPH6.
1MSD, Prague, Czech Republic, 2Lumanity, Sheffield, United Kingdom, 3Lumanity, Utrecht, Netherlands, 4MSD, Lisbon, Portugal, 5MSD (UK) Limited, London, United Kingdom, 6Value & Implementation Outcomes Research, MSD Sharp & Dohme GmbH, Munich, Germany.
1MSD, Prague, Czech Republic, 2Lumanity, Sheffield, United Kingdom, 3Lumanity, Utrecht, Netherlands, 4MSD, Lisbon, Portugal, 5MSD (UK) Limited, London, United Kingdom, 6Value & Implementation Outcomes Research, MSD Sharp & Dohme GmbH, Munich, Germany.
OBJECTIVES: Programmed cell death protein 1 (PD-1) inhibitor pembrolizumab substantially improves survival and quality of life across multiple early-stage and metastatic solid tumors. As its reimbursement expands in the Czech Republic, comprehensive population-level evidence on its impact is crucial, and this study aims to estimate clinical and humanistic outcomes associated with pembrolizumab treatment from 2018 to 2024 and project its future impact through 2030.
METHODS: Health state transition models previously approved by the Czech HTA agency (SUKL) for 13 publicly reimbursed pembrolizumab indications were combined in a population-level analysis. Model simulations estimated disease progression of pembrolizumab versus relevant comparator therapies, using efficacy data from KEYNOTE trials, along with local epidemiological and demographic data for the Czech Republic. Patients treated and projected to be treated with pembrolizumab for these 13 indications during 2018-2024 and 2025-2030, respectively, were included. Outcomes included tumor progressions and deaths averted during the examined periods, and lifetime gains in terms of life years (LYs) and Quality-adjusted life years (QALYs) (undiscounted) for patients initiating treatment during the examined periods.
RESULTS: During 2018-2024, 6,616 patients were treated with pembrolizumab in the Czech Republic across 13 indications, leading to 617 averted disease progressions and 755 averted deaths, and lifetime gains of 15,165 LYs and 11,708 QALYs; first-line treatment of metastatic non-small cell lung cancer accounted for 50.0% and 55.1% of the progressions and deaths averted, respectively, and 37.0% and 37.5% of the lifetime LYs and QALYs gained, respectively. Pembrolizumab use during 2025-2030 in a projected population of 14,115 patients was estimated to result in 1,552 additional averted progressions and 1,699 averted deaths, and lifetime gains of 33,319 LYs and 25,636 QALYs.
CONCLUSIONS: Pembrolizumab treatment across multiple early and advanced cancer indications is projected to lead to substantial clinical and humanistic benefits in the Czech Republic.
METHODS: Health state transition models previously approved by the Czech HTA agency (SUKL) for 13 publicly reimbursed pembrolizumab indications were combined in a population-level analysis. Model simulations estimated disease progression of pembrolizumab versus relevant comparator therapies, using efficacy data from KEYNOTE trials, along with local epidemiological and demographic data for the Czech Republic. Patients treated and projected to be treated with pembrolizumab for these 13 indications during 2018-2024 and 2025-2030, respectively, were included. Outcomes included tumor progressions and deaths averted during the examined periods, and lifetime gains in terms of life years (LYs) and Quality-adjusted life years (QALYs) (undiscounted) for patients initiating treatment during the examined periods.
RESULTS: During 2018-2024, 6,616 patients were treated with pembrolizumab in the Czech Republic across 13 indications, leading to 617 averted disease progressions and 755 averted deaths, and lifetime gains of 15,165 LYs and 11,708 QALYs; first-line treatment of metastatic non-small cell lung cancer accounted for 50.0% and 55.1% of the progressions and deaths averted, respectively, and 37.0% and 37.5% of the lifetime LYs and QALYs gained, respectively. Pembrolizumab use during 2025-2030 in a projected population of 14,115 patients was estimated to result in 1,552 additional averted progressions and 1,699 averted deaths, and lifetime gains of 33,319 LYs and 25,636 QALYs.
CONCLUSIONS: Pembrolizumab treatment across multiple early and advanced cancer indications is projected to lead to substantial clinical and humanistic benefits in the Czech Republic.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO127
Topic
Clinical Outcomes, Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Oncology